Health

STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 13:06:24 UTC.

Briefings

The article reports on a proposed U.S. Treasury rule requiring Pharmacy Benefit Managers (PBMs) to disclose granular payment details to clients, including rebates and payments from drugmakers. This disclosure is intended to prevent patients from being steered toward specific drugs. The rule applies to self-insured employers starting in July and is more aggressive than anticipated, with a Treasury official stating licensing deals are exempt from the new reporting requirements.

Key points

• A new U.S. Treasury rule requires Pharmacy Benefit Managers (PBMs) to disclose granular payment details to clients, including rebates and payments from drugmakers, effective July 2026.
• The rule applies to self-insured employers and is more aggressive than anticipated, with a Treasury official stating licensing deals are exempt from the new reporting requirements.

Context

The article discusses a recent U.S. Department of Treasury proposal to limit U.S. investment in the Chinese biotech industry. The main debate has shifted to the impact of the proposed rule, which is more aggressive than anticipated. The Wall Street Journal reports that the new regulation will take effect in July and apply to self-insured employers.

Limitations

The evidence is limited to a single article from October 2026. The article does not provide specific dates for the rule's implementation beyond July 2026, nor does it contain specific numbers or names of affected companies. The source does not specify the exact scope of the Treasury's investment limits or the full impact on the U.S. biotech sector.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 13:49:16 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidvx56k6ayavnxnmpu63wt4h3mafmsm5jwoq264vdtt77cfiucoxi